Expertise in
13
conditions

Dr. Ralph A. Defronzo

Endocrinology
701 S Zarzamora St, 
San Antonio, TX 
Expertise in
13
conditions
701 S Zarzamora St, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ralph Defronzo is an Endocrinologist in San Antonio, Texas. Dr. Defronzo is highly rated in 13 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Obesity, Congenital Hyperinsulinism, Gastric Bypass, and Sleeve Gastrectomy.

His clinical research consists of co-authoring 270 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Sendero
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

701 S Zarzamora St, San Antonio, TX 78207

Additional Areas of Focus

Dr. Defronzo has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Other
Study Phase: Early Phase 1
Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes
Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes
Enrollment Status: Completed
Publish Date: September 05, 2024
Intervention Type: Drug
Study Drugs: Metformin, Pioglitazone, Exenatide, Glyburide, Glargine
Study Phase: Phase 4
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in Type 2 Diabetes Mellitus (T2DM)
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in Type 2 Diabetes Mellitus (T2DM)
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drug: REMD-477
Study Phase: Early Phase 1
Randomized, Double-Blind, Sham-Controlled, Prospective, Multi-Center Pilot Study to Evaluate the Safety and Effectiveness of Duodenal Mucosal Resurfacing Using the Revita™ System in the Treatment of Type 2 Diabetes
Randomized, Double-Blind, Sham-Controlled, Prospective, Multi-Center Pilot Study to Evaluate the Safety and Effectiveness of Duodenal Mucosal Resurfacing Using the Revita™ System in the Treatment of Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 14, 2024
Intervention Type: Device
Study Phase: Not Applicable
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Enrollment Status: Completed
Publish Date: November 30, 2023
Intervention Type: Drug
Study Drugs: Dapagliflozin, Metformin, Glipizide
Study Phase: Phase 4
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
Enrollment Status: Completed
Publish Date: April 14, 2022
Intervention Type: Drug
Study Drugs: Glimepiride, Sitagliptin, Liraglutide, Insulin (glargine)
Study Phase: Phase 3
SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION Significance - PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION Significance - PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
Enrollment Status: Completed
Publish Date: September 17, 2020
Intervention Type: Drug
Study Phase: Phase 4
Protocol 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secretion
Protocol 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secretion
Enrollment Status: Completed
Publish Date: September 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
Enrollment Status: Completed
Publish Date: December 18, 2019
Intervention Type: Drug
Study Phase: Not Applicable
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (P2)
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (P2)
Enrollment Status: Completed
Publish Date: December 18, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy
A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy
Enrollment Status: Completed
Publish Date: August 14, 2019
Intervention Type: Drug
Study Phase: Not Applicable
Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled on GLP-1 Analogue Therapy
Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled on GLP-1 Analogue Therapy
Enrollment Status: Completed
Publish Date: June 21, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)
A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

270 Total Publications

Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries.
Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries.
Journal: medRxiv : the preprint server for health sciences
Published: August 08, 2025
Similar Doctors
Expertise in
41
conditions
Dr. Ameer Khowaja
Endocrinology
Expertise in
41
conditions
Dr. Ameer Khowaja
Endocrinology

Northeast Endocrinolgy Associates

7323 N Loop 1604, Suite 601, 
San Antonio, TX 
 (13.7 miles away)
210-650-3360
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ameer Khowaja is an Endocrinologist in San Antonio, Texas. Dr. Khowaja is highly rated in 41 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Hyperthyroidism, and Pituitary Tumor.

Expertise in
50
conditions
Dr. Shahid Aziz
Endocrinology
Expertise in
50
conditions
Dr. Shahid Aziz
Endocrinology

San Antonio Endocrinology And Diabetes Care PLLC

11130 Christus Hls, Suite 101, 
San Antonio, TX 
 (10.5 miles away)
210-352-5006
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shahid Aziz is an Endocrinologist in San Antonio, Texas. Dr. Aziz is highly rated in 50 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Hypothyroidism, Obesity in Children, and Type 1 Diabetes (T1D).

Expertise in
29
conditions
Dr. Jaime Cruz
Endocrinology
Expertise in
29
conditions
Dr. Jaime Cruz
Endocrinology
155 E Sonterra Blvd, Suite 105, 
San Antonio, TX 
 (13.7 miles away)
210-314-8045
Languages Spoken:
English
See accepted insurances

Jaime Cruz is an Endocrinologist in San Antonio, Texas. Dr. Cruz is highly rated in 29 conditions, according to our data. His top areas of expertise are Hashimoto Thyroiditis, Graves Disease, Thyroid Storm, and Obesity in Children.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Defronzo's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile